Canavan Disease clinical trials at UCSF
1 research study open to eligible people
Canavan Disease is a rare illness. UCSF has a clinical trial for it. This trial is testing a new gene therapy called BBP-812. The main goal is to make sure it is safe and acceptable for patients with Canavan Disease.
open to eligible people ages up to 30 months
The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.
Oakland, California and other locations
Our lead scientists for Canavan Disease research studies include Alexander Fay, MD.